Princeton Global Asset Management’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$62.9K Buy
695
+5
+0.7% +$419 0.01% 335
2026
Q1
$55.3K Hold
690
0.01% 343
2025
Q4
$58.8K Hold
690
0.01% 333
2025
Q3
$53.7K Hold
690
0.01% 313
2025
Q2
$54K Hold
690
0.01% 303
2025
Q1
$50K Sell
690
-10
-1% -$716 0.01% 301
2024
Q4
$51.8K Hold
700
0.01% 314
2024
Q3
$46.2K Hold
700
0.01% 330
2024
Q2
$64.7K Hold
700
0.01% 257
2024
Q1
$66.9K Hold
700
0.02% 228
2023
Q4
$53.4K Hold
700
0.01% 257
2023
Q3
$48.5K Hold
700
0.01% 255
2023
Q2
$66K Hold
700
0.02% 230
2023
Q1
$57.9K Hold
700
0.02% 247
2022
Q4
$52K Hold
700
0.02% 236
2022
Q3
$58K Hold
700
0.02% 224
2022
Q2
$67K Sell
700
-100
-13% -$10.4K 0.02% 225
2022
Q1
$94K Buy
+800
New +$89.7K 0.03% 210
2020
Q3
Sell
-336
Closed -$23K 475
2020
Q2
$23K Hold
336
0.01% 327
2020
Q1
$21K Hold
336
0.01% 298
2019
Q4
$26 Buy
+336
New +$26.2K 0.01% 301

Other funds holding EW

Princeton Global Asset Management's EW Position: Q2 2026 in Review

Princeton Global Asset Management increased its Edwards Lifesciences (EW) stake by 0.72% in Q2 2026, buying an estimated $419 and bringing the position to 695 shares worth $62.9K. The position accounts for 0.01% of the portfolio, ranked #335.

Princeton Global Asset Management first reported a position in EW in Q4 2019 and has held it in 21 quarters since. The position peaked at $94K in Q1 2022. 296 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Princeton Global Asset Management held 695 shares of Edwards Lifesciences worth $62.9K as of Q2 2026.
  • Princeton Global Asset Management bought 5 Edwards Lifesciences shares in Q2 2026, an estimated $419.
  • Edwards Lifesciences made up 0.01% of Princeton Global Asset Management's portfolio in Q2 2026, its #335 holding.
  • Princeton Global Asset Management first reported a position in Edwards Lifesciences in Q4 2019 and has held it in 21 quarters since.
  • Princeton Global Asset Management's Edwards Lifesciences position peaked at $94K in Q1 2022.
  • 296 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Princeton Global Asset Management's 13F filing for Q2 2026, filed 16 Jul 2026.